Response to the editorial “COVID-19 in patients with cardiovascular diseases” : Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes - 18/05/20

Réponse à l’éditorial, « Response to the editorial “COVID19 et maladies cardiovasculaires” »

Christian Funck-Brentano ^{a, ⁎} , Joe-Elie Salem ^a, Lee S. Nguyen ^b, Milou-Daniel Drici ^c, Dan M. Roden ^d

^a Pitié-Salpêtrière Hospital, AP–HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France 

^b Intensive Care Medicine department, Cochin University Hospital, AP–HP Centre, 75014 Paris, France 

^c Department of Pharmacology and Toxicology, PharmacoVigilance Centre, Hôpital de Cimiez, University of Nice Côte d’Azur Medical Centre, 06003, Nice, France 

^d Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA 

^⁎Corresponding author at: Department of Pharmacology, Sorbonne Université, CIC Paris-Est, AP–HP, 47–83, boulevard de l’Hôpital, bât. de la Force, 75013 Paris, France.Department of Pharmacology, Sorbonne Université, CIC Paris-Est, AP–HP47–83, boulevard de l’Hôpital, bât. de la ForceParis75013France

Le texte complet de cet article est disponible en PDF.